ENTITY
Patient Dies from Thrombotic Stroke in Pfizer’s Hympavzi Hemophilia Trial After Minor Surgery
Pfizer; Hympavzi; marstacimab; hemophilia; thrombotic stroke; patient death; clinical trial
Neurocrine’s VMAT2 Inhibitor Valbenazine Fails in Phase 3 Trial for Dyskinetic Cerebral Palsy
Neurocrine; valbenazine; VMAT2 inhibitor; dyskinetic cerebral palsy; KINECT-DCP; Phase 3 trial; chorea
Novo Nordisk Wins FDA Approval for First Oral GLP-1 Wegovy Pill in Obesity Treatment
Novo Nordisk; Wegovy pill; FDA approval; oral semaglutide; obesity treatment; GLP-1
FDA Approves Novo Nordisk’s Wegovy Pill as First Oral GLP-1 for Weight Management
Novo Nordisk; Wegovy pill; FDA approval; obesity treatment; oral semaglutide
Aktis Oncology Files for IPO to Fund Lilly-Partnered Radiopharma Pipeline
Aktis Oncology; IPO; Eli Lilly; radiopharmaceuticals; AKY-1189; AKTS
Spotlight On: Five Key FDA Approvals of 2025
FDA approvals; 2025; orphan drugs; novel therapies; rare diseases
Brainomix AI Reveals Hidden Efficacy of ARG-007 in Severe Stroke Patients
Brainomix; AI; stroke trial; ARG-007; neuroprotective; Argenica Therapeutics; Brainomix 360 Stroke
Breakthrough Real-World Evidence Powering Blood Cancer Research in 2025
RWE; blood cancer; real-world evidence; ASH 2025; SOHO 2025; hematologic care
AstraZeneca Pays $100M Upfront, Up to $2B Total for Jacobio’s Pan-KRAS Inhibitor JAB-23E73
AstraZeneca; Jacobio Pharma; JAB-23E73; pan-KRAS inhibitor; cancer drug; licensing deal; $100M upfront; $2B milestones
FDA Approves Cytokinetics’ Myqorzo for Obstructive Hypertrophic Cardiomyopathy, Positioning It Against BMS’s Camzyos
FDA approval; Cytokinetics; Myqorzo; aficamten; obstructive hypertrophic cardiomyopathy; Bristol Myers Squibb; Camzyos